- Telix Pharmaceuticals press release (TLX): Q3 revenue of US$245 million increased 19% over the prior corresponding quarter (Q3 2025) driven by continued strong demand for the commercial portfolio, in line with expectations. September sales drove a higher quarterly exit rate indicating continued strength
Telix Pharmaceuticals reports Q3 results (TLX:NASDAQ)
